ArticleClinical pharmacology and therapeutics2026
Serious Infection in Crohn's Disease Patients Treated With Ustekinumab: US Food and Drug Administration Active Postmarket Risk Identification and Analysis in the Sentinel Initiative.
Joel L Weissfeld et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.